AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01914081 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
Study NCT00531336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of Bevacizumab (Avastin)
Description: 1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
Study NCT00531336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of Bevacizumab (Avastin)
Description: 1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
Study NCT02657824 — intervention group
Intervention type: OTHER
Intervention: dyspneic patients
Description: measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
Study NCT02288481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Description: TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
Study NCT02288481 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension
Study NCT01724944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic pelvic and aortic lymphadenectomy
Description: Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
Study NCT02066727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
Study NCT02066727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is administrated as an adjuvant of lidocaine.
Study NCT00531336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaptanib (Macugen)
Description: 0.3 mg intravitreally applied every 6 weeks as long as required
Study NCT00531336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaptanib (Macugen)
Description: 0.3 mg intravitreally applied every 6 weeks as long as required
Study NCT03831542 — intervention group
Intervention type: BEHAVIORAL
Intervention: direct follicular aspiration
Description: direct follicular aspiration
Study NCT03831542 — intervention group
Intervention type: BEHAVIORAL
Intervention: follicular flushing
Description: follicular flushing
Study NCT02417441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eeva
Description: Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
Study NCT01489852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17beta-estradiol
Description: Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
Study NCT03428399 — intervention group
Intervention type: OTHER
Intervention: Psychosocial variables
Description: The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
Study NCT00162097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz containing antiretroviral regimen
Description: Capsule or Tablet, Oral, once daily for 2 days
Study NCT00162097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz containing antiretroviral regimen
Description: Capsule or Tablet, Oral, once daily for 2 days
Study NCT01411514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
Study NCT01411514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets. They will be administered during 25 days
Study NCT03420287 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MPM Prepared From Allogenic Bone Graft
Description: patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure
Study NCT03420287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone
Description: patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
Study NCT05103306 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin 25 MG
Description: Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
Study NCT05103306 — intervention group
Intervention type: DRUG
Intervention: INS
Description: Basal insulin add on the background OADs
Study NCT04324528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vv-ECMO + cytokine adsorption (Cytosorb adsorber)
Description: in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
Study NCT03567044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
Study NCT01252355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT01252355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration
Study NCT01252355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta (IFN-beta)
Description: Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert.
Study NCT01252355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Description: Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert.
Study NCT00538772 — intervention group
Intervention type: OTHER
Intervention: Not applicable - blood tests/tissue specimen tests will be undertaken
Description: Not applicable - blood tests/tissue specimen tests will be undertaken
Study NCT02566564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopain
Description: intra-articular injection
Study NCT04324528 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: vv-ECMO only (no cytokine adsorption)
Description: COVID-19-diseased treated with vv-ECMO
Study NCT00520624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle strength training
Study NCT00520624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT04812743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorectal Health Research Champions
Description: 20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs.
Study NCT05398549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise
Study NCT05398549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Description: group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414. Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training.
Study NCT02520583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactic acid bacteria and bifidobacteria
Study NCT02520583 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04162002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft
Description: Filler Injection
Study NCT04046458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nighttime Vital Sign EHR Alert
Description: A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.
Study NCT04046458 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No EHR alert
Description: No change to EHR function; no alert visible to providers
Study NCT03805776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting (diet restruction for specific period)
Description: 12-14 hours fasting
Study NCT04867447 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological trauma evaluation
Description: Psychological trauma exposure is assessed by validated scales:~* Childhood Trauma Questionnaire (CTQ)~* Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~* Cumulative Trauma Scale.~* The Holmes and Rahe Stress Scale.~Other clinical scales used:~* Positive and Negative Syndrome Scale (PANSS).~* Dissociative Experiences Scale (DES)~* Mini-Mental State Examination (MMSE).
Study NCT03423927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis + Self-care
Description: Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
Study NCT03600415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low altitude: 470m above sea level
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT03600415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Säntis; 2500m above sea level
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT00930345 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib (SUTENT)
Description: Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator.
Study NCT04382235 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive ventilatory support
Description: All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
Study NCT01061099 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells
Description: Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
Study NCT03099252 — intervention group
Intervention type: OTHER
Intervention: Parent-targeted BSweet2Babies video
Description: The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
Study NCT02656589 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
Study NCT02656589 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
Study NCT00813722 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: phone call
Description: patients received or not phone calls to give orientation abou treatment
Study NCT00813722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: phone call
Description: patients received or not phone calls to give orientation abou treatment
Study NCT00813722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine (calcium chanel blocker) and losartan (at1 antagonist)
Description: 2,5 mg tid and 25 mg tid
Study NCT00813722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol (beta blocker) and hydrochlorothiazide (diuretic)
Description: 25 mg tid and 12,5 mg tid
Study NCT03321279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentive
Description: Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
Study NCT03450499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: the analgesic affects of ketamine will be compared between the experimental and placebo group.
Study NCT03450499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the analgesic requirement will be calculated in placebo group.
Study NCT03506659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUDO-SCAN Device
Description: Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
Study NCT03506659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUDO-SCAN Device
Description: Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
Study NCT04726774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Two sessions of hypnosis, about 30 minutes each, weekly provided, by a physician trained in medical hypnosis.~Each session was realized as possible during walking, according to the agreement and the physical status of the participant.~Each sessions of hypnosis includes 3 phases : induction, walk perception alteration and post-hypnotic suggestion.
Study NCT04726774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
Study NCT04726774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
Study NCT04177966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre-prepared video describing the cesarean surgery
Description: a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
Study NCT04177966 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: general information
Description: In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
Study NCT00797394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of 2007RD01 and saw palmetto lipidic extract
Description: Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
Study NCT00797394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saw palmetto lipidic extract
Description: Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
Study NCT00332774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic solution 0.1%
Description: 1 drop 4 times daily for 90 days
Study NCT01389089 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ice gel pack
Description: ice gel pack combined with elevation
Study NCT01389089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-layer compression bandage
Description: Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
Study NCT00332774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine ophthalmic solution 0.4%
Description: 1 drop 4 times daily for 90 days
Study NCT00332774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac ophthalmic suspension vehicle
Study NCT03812263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L201
Description: CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
Study NCT04708899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: arabic version of differential processing training program
Description: comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
Study NCT04708899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arabic computer based auditory traing program(CBAT)
Description: comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
Study NCT03280706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Maltodextrin 50g in water 500ml
Study NCT03280706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange Juice
Description: Orange juice 480ml + 20ml of water
Study NCT03280706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee with milk
Description: Coffee with milk (330 ml of milk + 220 of water)
Study NCT00478088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoDisc
Description: The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
Study NCT00478088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrumented Anterior Cervical Discectomy and Fusion (ACDF)
Description: Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
Study NCT01543737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3ml hyaluronic acid (DUROLANE)
Description: DUROLANE Hyaluronic acid 20mg/ml
Study NCT01543737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2ml hyaluronic acid, (HYALGAN)
Description: HYALGAN Hyaluronic acid 10mg/ml
Study NCT02084017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena (Negative Pressure Wound Therapy Device)
Description: No other details required.